531 related articles for article (PubMed ID: 19531787)
1. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.
Segal JB; Brotman DJ; Necochea AJ; Emadi A; Samal L; Wilson LM; Crim MT; Bass EB
JAMA; 2009 Jun; 301(23):2472-85. PubMed ID: 19531787
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of genetic testing in adults with a history of venous thromboembolism.
Segal JB; Brotman DJ; Emadi A; Necochea AJ; Samal L; Wilson LM; Crim MT; Bass EB
Evid Rep Technol Assess (Full Rep); 2009 Jun; (180):1-162. PubMed ID: 20629476
[TBL] [Abstract][Full Text] [Related]
3. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2011 Jan; 13(1):67-76. PubMed ID: 21150787
[TBL] [Abstract][Full Text] [Related]
4. Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?
Méan M; Limacher A; Stalder O; Angelillo-Scherrer A; Alberio L; Fontana P; Beer HJ; Rodondi N; Lämmle B; Aujesky D
Am J Med; 2017 Oct; 130(10):1220.e17-1220.e22. PubMed ID: 28606797
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.
Ho WK; Hankey GJ; Quinlan DJ; Eikelboom JW
Arch Intern Med; 2006 Apr; 166(7):729-36. PubMed ID: 16606808
[TBL] [Abstract][Full Text] [Related]
6. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
Marchiori A; Mosena L; Prins MH; Prandoni P
Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
[TBL] [Abstract][Full Text] [Related]
7. Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation.
Cordoba I; Pegenaute C; González-López TJ; Chillon C; Sarasquete ME; Martin-Herrero F; Guerrero C; Cabrero M; Garcia Sanchez MH; Pabon P; Lozano FS; Gonzalez M; Alberca I; González-Porras JR
Eur J Haematol; 2012 Sep; 89(3):250-5. PubMed ID: 22642978
[TBL] [Abstract][Full Text] [Related]
8. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.
van Vlijmen EF; Wiewel-Verschueren S; Monster TB; Meijer K
J Thromb Haemost; 2016 Jul; 14(7):1393-403. PubMed ID: 27121914
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians.
Nusier MK; Radaideh AM; Ababneh NA; Qaqish BM; Alzoubi R; Khader Y; Mersa JY; Irshaid NM; El-Khateeb M
Neuro Endocrinol Lett; 2007 Oct; 28(5):699-703. PubMed ID: 17984931
[TBL] [Abstract][Full Text] [Related]
10. High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A.
Federici EH; Al-Mondhiry H
Thromb Res; 2019 Oct; 182():75-78. PubMed ID: 31472339
[TBL] [Abstract][Full Text] [Related]
11. Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms.
Bucciarelli P; De Stefano V; Passamonti SM; Tormene D; Legnani C; Rossi E; Castaman G; Simioni P; Cini M; Martinelli I
Blood; 2013 Oct; 122(15):2555-61. PubMed ID: 23913469
[TBL] [Abstract][Full Text] [Related]
12. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis.
Qi X; Ren W; De Stefano V; Fan D
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1801-12.e7. PubMed ID: 24793031
[TBL] [Abstract][Full Text] [Related]
13. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.
Caiano L; Kovacs MJ; Lazo-Langner A; Anderson DR; Kahn SR; Shah V; Kaatz S; Zide RS; Schulman S; Chagnon I; Mallick R; Rodger MA; Wells PS
J Thromb Haemost; 2023 Mar; 21(3):553-558. PubMed ID: 36710196
[TBL] [Abstract][Full Text] [Related]
14. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.
Miles JS; Miletich JP; Goldhaber SZ; Hennekens CH; Ridker PM
J Am Coll Cardiol; 2001 Jan; 37(1):215-8. PubMed ID: 11153741
[TBL] [Abstract][Full Text] [Related]
15. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population.
Moussaoui S; Saussoy P; Ambroise J; Defour JP; Zouitene R; Sifi K; Abadi N
Clin Appl Thromb Hemost; 2017 Mar; 23(2):105-115. PubMed ID: 26304686
[TBL] [Abstract][Full Text] [Related]
16. Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
Saemundsson Y; Sveinsdottir SV; Svantesson H; Svensson PJ
J Thromb Thrombolysis; 2013 Oct; 36(3):324-31. PubMed ID: 23054468
[TBL] [Abstract][Full Text] [Related]
17. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk.
Ziakas PD; Poulou LS; Pavlou M; Zintzaras E
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():106-11. PubMed ID: 26115054
[TBL] [Abstract][Full Text] [Related]
18. Type and location of venous thromboembolism in carriers of Factor V Leiden or prothrombin G20210A mutation versus patients with no mutation.
Kovac M; Mitic G; Mikovic Z; Antonijevic N; Djordjevic V; Mikovic D; Mandic V; Rakicevic L; Radojkovic D
Clin Appl Thromb Hemost; 2010 Feb; 16(1):66-70. PubMed ID: 18796457
[TBL] [Abstract][Full Text] [Related]
19. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.
Simone B; De Stefano V; Leoncini E; Zacho J; Martinelli I; Emmerich J; Rossi E; Folsom AR; Almawi WY; Scarabin PY; den Heijer M; Cushman M; Penco S; Vaya A; Angchaisuksiri P; Okumus G; Gemmati D; Cima S; Akar N; Oguzulgen KI; Ducros V; Lichy C; Fernandez-Miranda C; Szczeklik A; Nieto JA; Torres JD; Le Cam-Duchez V; Ivanov P; Cantu-Brito C; Shmeleva VM; Stegnar M; Ogunyemi D; Eid SS; Nicolotti N; De Feo E; Ricciardi W; Boccia S
Eur J Epidemiol; 2013 Aug; 28(8):621-47. PubMed ID: 23900608
[TBL] [Abstract][Full Text] [Related]
20. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.
Wu O; Robertson L; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Langhorne P; Brenkel I; Regan L; Greer I
Health Technol Assess; 2006 Apr; 10(11):1-110. PubMed ID: 16595080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
